Barry begins his research in cardiovascular biomechanics, working alongside clinicians, medical imaging experts, scientists and engineers in Ireland, Scotland and internationally. Early prototype computer models are developed across a range of cardiovascular diseases, laying the foundation for future work.

The Vascular Engineering Lab (VascLab) is established by A/Prof Barry Doyle, a biomedical engineer at UWA, with a focus on using engineering to better understand heart disease.

Collaboration begins with Prof Carl Schultz, a cardiologist at UWA and the Royal Perth Hospital, on coronary artery disease. Lachlan Kelsey begins his PhD on the project.

VascLab moves to the Harry Perkins Institute of Medical Research and the lab’s focus on medical devices to treat cardiovascular disease begins to accelerate.

Project results are encouraging and efforts begin to commercialize software technology, with help from Dr Sam South at UWA.

Lachlan completes his PhD and UWA commences the spin-out process. De-risking activities are performed with the product development company Planet Innovation.

A voice of customer study is performed with Curve Tomorrow and further de-risking is performed through ANDHealth workshops.

Barry starts Navier Medical Limited as the company spins out of the UWA and the Harry Perkins Institute of Medical Research, with Lachlan joining as employee #1. Otto Buttula takes a stake in the company, and Barry connects with Sander Bangma. Jonathan Tapley joins the company to accelerate the development and implementation of our AI models.

Navier wins the WA Innovator of the Year Award in the Emerging Innovation category.

Otto joins the company as Executive Chairman, Sander commences as CEO and Barry moves to an Adjunct position at UWA and becomes CTO. Navier Medical is awarded the ‘Most Outstanding Patient Innovation’ by the Australian Patients Association.

Navier moves into a new HQ and begins to build its culture while also progressing with technical development and marketing approvals of its first product, Mosaic.

Navier is accepted into the prestigious ANDHealth+ Grow program, establishes a world-class Advisory Board, and makes huge progress on the product development of Mosaic V1, submitting the 510(k) application on Christmas Day!

Mosaic V1 receives clearance by the FDA marking a major milestone for the company! Additional non-dilutive funding awarded by the WA Government. Further product development efforts start to accelerate as the company expands its portfolio.